Data / Drug companies / Hospira, Inc.
Hospira, Inc.: 28 products in the FDA NDC directory, labeler code 61703
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Hospira, Inc. (labeler code 61703) lists 28 products in the FDA National Drug Code Directory, covering 10 finished drugs by generic name. By type: 28 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on April 8, 2025.
The request: Watch Hospira, Inc. (FDA labeler code 61703): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 61703
- Products in commercial distribution
- 28
- Packages
- 40
- Finished drugs by generic name
- 10
- Prescription products
- 28
- Over the counter products
- 0
- Flagged as original packager
- 17 of 17 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- June 4, 1990
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 22 | 78.6% |
| New drug applications (NDA) | 6 | 21.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 28 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Methotrexate | 6 | 31 |
| Carboplatin | 5 | 11 |
| Cytarabine | 5 | 5 |
| Pamidronate disodium | 3 | 2 |
| Vincristine sulfate | 2 | 1 |
| Bleomycin | 2 | 4 |
| Paclitaxel | 2 | 20 |
| Mitoxantrone | 1 | 2 |
| Irinotecan hydrochloride | 1 | 12 |
| Oxaliplatin | 1 | 16 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 24 | 85.7% |
| Injection, solution, concentrate | 2 | 7.1% |
| Injection, powder, lyophilized, for solution | 2 | 7.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Folate Analog Metabolic Inhibitor | 6 |
| Platinum-based Drug | 6 |
| Nucleoside Metabolic Inhibitor | 5 |
| Bisphosphonate | 3 |
| Topoisomerase Inhibitor | 2 |
| Vinca Alkaloid | 2 |
| Cytoprotective Agent | 2 |
| Microtubule Inhibitor | 2 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Paclitaxel | 61703-015 | Injection, solution | Generic drugs (ANDA) | April 8, 2025 |
| Cytarabine | 61703-155 | Injection, solution | Generic drugs (ANDA) | April 7, 2025 |
| Methotrexate | 61703-161 | Injection, solution | New drug applications (NDA) | November 4, 2024 |
| Methotrexate | 61703-124 | Injection, solution | New drug applications (NDA) | October 17, 2022 |
| Carboplatin | 61703-600 | Injection, solution | Generic drugs (ANDA) | May 23, 2022 |
| Carboplatin | 61703-360 | Injection, solution | Generic drugs (ANDA) | May 23, 2022 |
| Carboplatin | 61703-262 | Injection, solution | Generic drugs (ANDA) | May 23, 2022 |
| Carboplatin | 61703-150 | Injection, solution | Generic drugs (ANDA) | May 23, 2022 |
| Methotrexate | 61703-350 | Injection, solution | New drug applications (NDA) | September 25, 2014 |
| VinCRIStine Sulfate | 61703-309 | Injection, solution | Generic drugs (ANDA) | November 27, 2013 |
| Methotrexate | 61703-408 | Injection, solution | New drug applications (NDA) | November 11, 2013 |
| Oxaliplatin | 61703-363 | Injection, solution, concentrate | Generic drugs (ANDA) | August 10, 2009 |
| Irinotecan Hydrochloride | 61703-349 | Injection, solution | Generic drugs (ANDA) | February 27, 2008 |
| Mitoxantrone | 61703-343 | Injection, solution, concentrate | Generic drugs (ANDA) | April 11, 2006 |
| Pamidronate Disodium | 61703-326 | Injection, solution | Generic drugs (ANDA) | October 1, 2005 |
| Pamidronate Disodium | 61703-324 | Injection, solution | Generic drugs (ANDA) | October 1, 2005 |
| Methotrexate | 61703-350 | Injection, solution | New drug applications (NDA) | July 27, 2005 |
| Carboplatin | 61703-339 | Injection, solution | Generic drugs (ANDA) | October 14, 2004 |
| Paclitaxel | 61703-342 | Injection, solution | Generic drugs (ANDA) | March 1, 2004 |
| Pamidronate Disodium | 61703-325 | Injection, solution | Generic drugs (ANDA) | July 28, 2003 |
| Methotrexate | 61703-408 | Injection, solution | New drug applications (NDA) | February 26, 2001 |
| Bleomycin | 61703-332 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 11, 2000 |
| Bleomycin | 61703-323 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 10, 2000 |
| Cytarabine | 61703-319 | Injection, solution | Generic drugs (ANDA) | November 22, 1999 |
| VinCRIStine Sulfate | 61703-309 | Injection, solution | Generic drugs (ANDA) | January 1, 1996 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.